Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
Condition: Relapsed or Refractory Multiple Myeloma Interventions: Drug: Carfilzomib; Drug: Dexamethasone; Drug: Pomalidomide Sponsor: Amgen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials